Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations.

Murakami H, Nokihara H, Hayashi H, Seto T, Park K, Azuma K, Tsai CM, Yang JC, Nishio M, Kim SW, Kiura K, Inoue A, Takeda K, Kang JH, Nakagawa T, Takeda K, Akazawa R, Kaneko Y, Shimazaki M, Morita S, Fukuoka M, Nakagawa K.

Cancer Sci. 2018 Jul 4. doi: 10.1111/cas.13724. [Epub ahead of print]

2.

Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies.

Tanaka M, Horinouchi H, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Ohe Y.

ESMO Open. 2018 May 5;3(4):e000342. doi: 10.1136/esmoopen-2018-000342. eCollection 2018.

3.

Long-term survival without surgery in NSCLC patients with synchronous brain oligometastasis: systemic chemotherapy revisited.

Sato J, Horinouchi H, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Ohe Y.

J Thorac Dis. 2018 Mar;10(3):1696-1702. doi: 10.21037/jtd.2018.03.08.

4.

Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study.

Hida T, Kaji R, Satouchi M, Ikeda N, Horiike A, Nokihara H, Seto T, Kawakami T, Nakagawa S, Kubo T.

Clin Lung Cancer. 2018 Jul;19(4):e405-e415. doi: 10.1016/j.cllc.2018.01.004. Epub 2018 Feb 1.

5.

Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial.

Horinouchi H, Kubota K, Miyanaga A, Nakamichi S, Seike M, Gemma A, Yamane Y, Kurimoto F, Sakai H, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Tamura T, Ohe Y.

ESMO Open. 2018 Jan 29;3(1):e000288. doi: 10.1136/esmoopen-2017-000288. eCollection 2018.

6.

Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression.

Seki Y, Fujiwara Y, Kohno T, Yoshida K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Yamamoto N, Kuwano K, Ohe Y.

ESMO Open. 2018 Feb 8;3(2):e000292. doi: 10.1136/esmoopen-2017-000292. eCollection 2018. No abstract available.

7.

Effect of sequential chemoradiotherapy in patients with limited-disease small-cell lung cancer who were ineligible for concurrent therapy: a retrospective study at two institutions.

Ohara S, Kanda S, Okuma H, Goto Y, Horinouchi H, Fujiwara Y, Nokihara H, Ito Y, Yamamoto N, Usui K, Homma S, Ohe Y.

Jpn J Clin Oncol. 2018 Jan 1;48(1):82-88. doi: 10.1093/jjco/hyx153.

PMID:
29136177
8.

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).

Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Soo RA, Yang JC, Sugawara S, Nishio M, Takahashi T, Goto K, Chang J, Maemondo M, Ichinose Y, Cheng Y, Lim WT, Morita S, Tamura T.

Ann Oncol. 2017 Nov 1;28(11):2698-2706. doi: 10.1093/annonc/mdx419.

9.

A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.

Katakami N, Felip E, Spigel DR, Kim JH, Olivo M, Guo M, Nokihara H, Yang JC, Iannotti N, Satouchi M, Barlesi F.

Ann Oncol. 2017 Sep 1;28(9):2241-2247. doi: 10.1093/annonc/mdx284.

10.

Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study.

Fujiwara Y, Yamazaki N, Kiyohara Y, Yoshikawa S, Yamamoto N, Tsutsumida A, Nokihara H, Namikawa K, Mukaiyama A, Zhang F, Tamura T.

Invest New Drugs. 2018 Apr;36(2):259-268. doi: 10.1007/s10637-017-0502-8. Epub 2017 Sep 7.

PMID:
28879519
11.

Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer.

Nishio M, Hida T, Atagi S, Sakai H, Nakagawa K, Takahashi T, Nogami N, Saka H, Takenoyama M, Maemondo M, Ohe Y, Nokihara H, Hirashima T, Tanaka H, Fujita S, Takeda K, Goto K, Satouchi M, Isobe H, Minato K, Sumiyoshi N, Tamura T.

ESMO Open. 2017 Mar 7;1(4):e000108. doi: 10.1136/esmoopen-2016-000108. eCollection 2016.

12.

PD-L1 expression in neuroendocrine tumors of the lung.

Tsuruoka K, Horinouchi H, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Asakura K, Nakagawa K, Sakurai H, Watanabe SI, Tsuta K, Ohe Y.

Lung Cancer. 2017 Jun;108:115-120. doi: 10.1016/j.lungcan.2017.03.006. Epub 2017 Mar 24.

13.

Comparison of Radiotherapy and Chemoradiotherapy for Locoregional Recurrence of Non-small-cell Lung Cancer Developing After Surgery.

Nakamichi S, Horinouchi H, Asao T, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Ito Y, Watanabe SI, Ohe Y.

Clin Lung Cancer. 2017 Nov;18(6):e441-e448. doi: 10.1016/j.cllc.2017.05.005. Epub 2017 May 10.

14.

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.

Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T.

Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10.

PMID:
28501140
15.

Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset.

Hida T, Satouchi M, Nakagawa K, Seto T, Matsumoto S, Kiura K, Nokihara H, Murakami H, Tokushige K, Hatano B, Nishio M.

Jpn J Clin Oncol. 2017 Jul 1;47(7):618-624. doi: 10.1093/jjco/hyx045.

PMID:
28369553
16.

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial.

Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, Nishio M, Kaneda H, Takayama K, Ishimoto O, Takeda K, Yoshioka H, Tachihara M, Sakai H, Goto K, Yamamoto N.

Lancet Oncol. 2017 May;18(5):663-671. doi: 10.1016/S1470-2045(17)30230-9. Epub 2017 Mar 23.

PMID:
28343976
17.

Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.

Hida T, Nishio M, Nogami N, Ohe Y, Nokihara H, Sakai H, Satouchi M, Nakagawa K, Takenoyama M, Isobe H, Fujita S, Tanaka H, Minato K, Takahashi T, Maemondo M, Takeda K, Saka H, Goto K, Atagi S, Hirashima T, Sumiyoshi N, Tamura T.

Cancer Sci. 2017 May;108(5):1000-1006. doi: 10.1111/cas.13225. Epub 2017 Apr 26.

18.

Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.

Katakami N, Hida T, Nokihara H, Imamura F, Sakai H, Atagi S, Nishio M, Kashii T, Satouchi M, Helwig C, Watanabe M, Tamura T.

Lung Cancer. 2017 Mar;105:23-30. doi: 10.1016/j.lungcan.2017.01.007. Epub 2017 Jan 17.

PMID:
28236981
19.

A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors.

Nokihara H, Yamamoto N, Yamada Y, Honda K, Asahina H, Tamura Y, Hozak RR, Gao L, Suzukawa K, Enatsu S, Tamura T.

Jpn J Clin Oncol. 2017 Apr 1;47(4):298-305. doi: 10.1093/jjco/hyx008.

PMID:
28158463
20.

Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.

Tambo Y, Hosomi Y, Sakai H, Nogami N, Atagi S, Sasaki Y, Kato T, Takahashi T, Seto T, Maemondo M, Nokihara H, Koyama R, Nakagawa K, Kawaguchi T, Okamura Y, Nakamura O, Nishio M, Tamura T.

Invest New Drugs. 2017 Apr;35(2):217-226. doi: 10.1007/s10637-017-0435-2. Epub 2017 Jan 30.

PMID:
28138828
21.

Randomized phase II study of sequential carboplatin plus paclitaxel and gefitinib in chemotherapy-naïve patients with advanced or metastatic non-small-cell lung cancer: Long-term follow-up results.

Kubo E, Yamamoto N, Nokihara H, Fujiwara Y, Horinouchi H, Kanda S, Goto Y, Ohe Y.

Mol Clin Oncol. 2017 Jan;6(1):56-62. doi: 10.3892/mco.2016.1076. Epub 2016 Nov 9.

22.

Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.

Asao T, Fujiwara Y, Itahashi K, Kitahara S, Goto Y, Horinouchi H, Kanda S, Nokihara H, Yamamoto N, Takahashi K, Ohe Y.

Clin Lung Cancer. 2017 Jul;18(4):e251-e258. doi: 10.1016/j.cllc.2016.11.015. Epub 2016 Dec 7.

PMID:
28065466
23.

Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations.

Seow WJ, Matsuo K, Hsiung CA, Shiraishi K, Song M, Kim HN, Wong MP, Hong YC, Hosgood HD 3rd, Wang Z, Chang IS, Wang JC, Chatterjee N, Tucker M, Wei H, Mitsudomi T, Zheng W, Kim JH, Zhou B, Caporaso NE, Albanes D, Shin MH, Chung LP, An SJ, Wang P, Zheng H, Yatabe Y, Zhang XC, Kim YT, Shu XO, Kim YC, Bassig BA, Chang J, Ho JC, Ji BT, Kubo M, Daigo Y, Ito H, Momozawa Y, Ashikawa K, Kamatani Y, Honda T, Sakamoto H, Kunitoh H, Tsuta K, Watanabe SI, Nokihara H, Miyagi Y, Nakayama H, Matsumoto S, Tsuboi M, Goto K, Yin Z, Shi J, Takahashi A, Goto A, Minamiya Y, Shimizu K, Tanaka K, Wu T, Wei F, Wong JY, Matsuda F, Su J, Kim YH, Oh IJ, Song F, Lee VH, Su WC, Chen YM, Chang GC, Chen KY, Huang MS, Yang PC, Lin HC, Xiang YB, Seow A, Park JY, Kweon SS, Chen CJ, Li H, Gao YT, Wu C, Qian B, Lu D, Liu J, Jeon HS, Hsiao CF, Sung JS, Tsai YH, Jung YJ, Guo H, Hu Z, Wang WC, Chung CC, Lawrence C, Burdett L, Yeager M, Jacobs KB, Hutchinson A, Berndt SI, He X, Wu W, Wang J, Li Y, Choi JE, Park KH, Sung SW, Liu L, Kang CH, Hu L, Chen CH, Yang TY, Xu J, Guan P, Tan W, Wang CL, Sihoe AD, Chen Y, Choi YY, Hung JY, Kim JS, Yoon HI, Cai Q, Lin CC, Park IK, Xu P, Dong J, Kim C, He Q, Perng RP, Chen CY, Vermeulen R, Wu J, Lim WY, Chen KC, Chan JK, Chu M, Li YJ, Li J, Chen H, Yu CJ, Jin L, Lo YL, Chen YH, Fraumeni JF Jr, Liu J, Yamaji T, Yang Y, Hicks B, Wyatt K, Li SA, Dai J, Ma H, Jin G, Song B, Wang Z, Cheng S, Li X, Ren Y, Cui P, Iwasaki M, Shimazu T, Tsugane S, Zhu J, Jiang G, Fei K, Wu G, Chien LH, Chen HL, Su YC, Tsai FY, Chen YS, Yu J, Stevens VL, Laird-Offringa IA, Marconett CN, Lin D, Chen K, Wu YL, Landi MT, Shen H, Rothman N, Kohno T, Chanock SJ, Lan Q.

Hum Mol Genet. 2017 Jan 15;26(2):454-465. doi: 10.1093/hmg/ddw414.

24.

PS01.49: Discrete and Limited Extent of N2 Nodes Associated with Better Outcome of Chemoradiotherapy: Effect of Pretreatment Pathological Diagnoses of N2: Topic: Radiation Oncology.

Horinouchi H, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Ito Y, Ohe Y.

J Thorac Oncol. 2016 Nov;11(11S):S299-S300. doi: 10.1016/j.jtho.2016.09.084. Epub 2016 Oct 28. No abstract available.

25.

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors.

Yamamoto N, Nokihara H, Yamada Y, Shibata T, Tamura Y, Seki Y, Honda K, Tanabe Y, Wakui H, Tamura T.

Invest New Drugs. 2017 Apr;35(2):207-216. doi: 10.1007/s10637-016-0411-2. Epub 2016 Dec 8.

26.

Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.

Okuma HS, Horinouchi H, Kitahara S, Asao T, Sunami K, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Ohe Y.

Clin Lung Cancer. 2017 Mar;18(2):234-240.e2. doi: 10.1016/j.cllc.2016.09.005. Epub 2016 Oct 25.

27.

Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors.

Tamura Y, Nokihara H, Honda K, Tanabe Y, Asahina H, Yamada Y, Enatsu S, Kurek R, Yamamoto N, Tamura T.

Cancer Chemother Pharmacol. 2016 Nov;78(5):995-1002. Epub 2016 Sep 15.

PMID:
27628194
28.

Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.

Kanda S, Goto K, Shiraishi H, Kubo E, Tanaka A, Utsumi H, Sunami K, Kitazono S, Mizugaki H, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Hozumi H, Tamura T.

Ann Oncol. 2016 Dec;27(12):2242-2250. doi: 10.1093/annonc/mdw416. Epub 2016 Oct 20.

29.

Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy.

Katsuya Y, Horinouchi H, Asao T, Kitahara S, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Watanabe S, Tsuta K, Ohe Y.

Lung Cancer. 2016 Sep;99:4-10. doi: 10.1016/j.lungcan.2016.05.007. Epub 2016 May 12.

30.

Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma.

Shiraishi K, Okada Y, Takahashi A, Kamatani Y, Momozawa Y, Ashikawa K, Kunitoh H, Matsumoto S, Takano A, Shimizu K, Goto A, Tsuta K, Watanabe S, Ohe Y, Watanabe Y, Goto Y, Nokihara H, Furuta K, Yoshida A, Goto K, Hishida T, Tsuboi M, Tsuchihara K, Miyagi Y, Nakayama H, Yokose T, Tanaka K, Nagashima T, Ohtaki Y, Maeda D, Imai K, Minamiya Y, Sakamoto H, Saito A, Shimada Y, Sunami K, Saito M, Inazawa J, Nakamura Y, Yoshida T, Yokota J, Matsuda F, Matsuo K, Daigo Y, Kubo M, Kohno T.

Nat Commun. 2016 Aug 9;7:12451. doi: 10.1038/ncomms12451.

31.

Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism.

Fujiwara Y, Hamada A, Mizugaki H, Aikawa H, Hata T, Horinouchi H, Kanda S, Goto Y, Itahashi K, Nokihara H, Yamamoto N, Ohe Y.

Cancer Sci. 2016 Aug;107(8):1117-23. doi: 10.1111/cas.12983. Epub 2016 Jul 21.

32.

Simultaneous optimization of limited sampling points for pharmacokinetic analysis of amrubicin and amrubicinol in cancer patients.

Makino Y, Watanabe M, Makihara RA, Nokihara H, Yamamoto N, Ohe Y, Sugiyama E, Sato H, Hayashi Y.

Asia Pac J Clin Oncol. 2016 Sep;12(3):259-64. doi: 10.1111/ajco.12485. Epub 2016 Mar 7.

PMID:
26948073
33.

Medical treatment involving investigational drugs and genetic profile of thymic carcinoma.

Asao T, Fujiwara Y, Sunami K, Kitahara S, Goto Y, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Ichikawa H, Kohno T, Tsuta K, Watanabe S, Takahashi K, Ohe Y.

Lung Cancer. 2016 Mar;93:77-81. doi: 10.1016/j.lungcan.2016.01.004. Epub 2016 Jan 11.

PMID:
26898618
34.

Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues.

Sunami K, Furuta K, Tsuta K, Sasada S, Izumo T, Nakaoku T, Shimada Y, Saito M, Nokihara H, Watanabe S, Ohe Y, Kohno T.

J Thorac Oncol. 2016 Feb;11(2):203-12. doi: 10.1016/j.jtho.2015.10.005. Epub 2015 Dec 19.

35.

Pharmacokinetics of Weekly Paclitaxel and Feasibility of Dexamethasone Taper in Japanese Patients with Advanced Non-small Cell Lung Cancer.

Nokihara H, Yamamoto N, Ohe Y, Hiraoka M, Tamura T.

Clin Ther. 2016 Feb;38(2):338-47. doi: 10.1016/j.clinthera.2015.12.009. Epub 2016 Jan 13.

36.

Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.

Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe S, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y.

Oncologist. 2016 Feb;21(2):156-64. doi: 10.1634/theoncologist.2015-0288. Epub 2016 Jan 14.

37.

Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity.

Horinouchi H, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Sumi M, Tamura T, Ohe Y.

Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):155-162. doi: 10.1016/j.ijrobp.2015.09.026. Epub 2015 Sep 26.

38.

Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma.

Tamura Y, Fujiwara Y, Yamamoto N, Nokihara H, Horinouchi H, Kanda S, Goto Y, Kubo E, Kitahara S, Tsuruoka K, Tsuta K, Ohe Y.

BMC Res Notes. 2015 Dec 18;8:800. doi: 10.1186/s13104-015-1762-z.

39.

Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.

Nokihara H, Yamada Y, Fujiwara Y, Yamamoto N, Wakui H, Nakamichi S, Kitazono S, Inoue K, Harada A, Taube T, Takeuchi Y, Tamura T.

Invest New Drugs. 2016 Feb;34(1):66-74. doi: 10.1007/s10637-015-0300-0. Epub 2015 Dec 2.

PMID:
26627079
40.

A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors.

Nakamichi S, Nokihara H, Yamamoto N, Yamada Y, Honda K, Tamura Y, Wakui H, Sasaki T, Yusa W, Fujino K, Tamura T.

Cancer Chemother Pharmacol. 2015 Dec;76(6):1153-61. doi: 10.1007/s00280-015-2899-0. Epub 2015 Nov 3.

41.

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.

Fujiwara Y, Nokihara H, Yamada Y, Yamamoto N, Sunami K, Utsumi H, Asou H, TakahashI O, Ogasawara K, Gueorguieva I, Tamura T.

Cancer Chemother Pharmacol. 2015 Dec;76(6):1143-52. doi: 10.1007/s00280-015-2895-4. Epub 2015 Nov 3.

PMID:
26526984
42.

A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).

Mizugaki H, Yamamoto N, Nokihara H, Fujiwara Y, Horinouchi H, Kanda S, Kitazono S, Yagishita S, Xiong H, Qian J, Hashiba H, Shepherd SP, Giranda V, Tamura T.

Cancer Chemother Pharmacol. 2015 Nov;76(5):1063-72. doi: 10.1007/s00280-015-2876-7. Epub 2015 Oct 3.

43.

Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs.

Nakata A, Yoshida R, Yamaguchi R, Yamauchi M, Tamada Y, Fujita A, Shimamura T, Imoto S, Higuchi T, Nomura M, Kimura T, Nokihara H, Higashiyama M, Kondoh K, Nishihara H, Tojo A, Yano S, Miyano S, Gotoh N.

Sci Rep. 2015 Aug 13;5:13076. doi: 10.1038/srep13076.

44.

Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.

Asao T, Nokihara H, Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Yamamoto N, Sekine I, Kunitoh H, Fujiwara Y, Ohe Y.

Jpn J Clin Oncol. 2015 Oct;45(10):941-6. doi: 10.1093/jjco/hyv107. Epub 2015 Jul 31.

PMID:
26232449
45.

Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer.

Yagishita S, Horinouchi H, Sunami KS, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Sumi M, Shiraishi K, Kohno T, Furuta K, Tsuta K, Tamura T, Ohe Y.

Cancer Sci. 2015 Oct;106(10):1402-7. doi: 10.1111/cas.12740. Epub 2015 Aug 18.

46.

Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.

Kanda S, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Kubota K, Tamura T, Ohe Y.

Lung Cancer. 2015 Sep;89(3):287-93. doi: 10.1016/j.lungcan.2015.06.016. Epub 2015 Jul 2.

PMID:
26169499
47.

Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer.

Katsuya Y, Fujiwara Y, Sunami K, Utsumi H, Goto Y, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Takashima Y, Osawa S, Ohe Y, Tamura T, Hamada A.

Cancer Chemother Pharmacol. 2015 Jul;76(1):125-32. doi: 10.1007/s00280-015-2778-8. Epub 2015 May 21.

PMID:
25994853
48.

Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.

Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Sasada S, Watanabe S, Asamura H, Tamura T, Ohe Y.

Clin Lung Cancer. 2015 Sep;16(5):385-90. doi: 10.1016/j.cllc.2015.03.008. Epub 2015 Apr 4.

PMID:
25937270
49.

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.

Horinouchi H, Yamamoto N, Fujiwara Y, Sekine I, Nokihara H, Kubota K, Kanda S, Yagishita S, Wakui H, Kitazono S, Mizugaki H, Tokudome T, Tamura T.

Invest New Drugs. 2015 Aug;33(4):881-9. doi: 10.1007/s10637-015-0243-5. Epub 2015 May 1.

50.

Current Status of Single-Agent Phase I Trials in Japan: Toward Globalization.

Mizugaki H, Yamamoto N, Fujiwara Y, Nokihara H, Yamada Y, Tamura T.

J Clin Oncol. 2015 Jun 20;33(18):2051-61. doi: 10.1200/JCO.2014.58.4953. Epub 2015 Apr 27. Erratum in: J Clin Oncol. 2015 Jul 20;33(21):2412.

PMID:
25918301

Supplemental Content

Loading ...
Support Center